Cargando…

A Novel Anti-B7-H3 × Anti-CD3 Bispecific Antibody with Potent Antitumor Activity

B7-H3 plays an important role in tumor apoptosis, proliferation, adhesion, angiogenesis, invasion, migration, and evasion of immune surveillance. It is overexpressed in various human solid tumor tissues. In patients, B7-H3 overexpression correlates with advanced stages, poor clinical outcomes, and r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Feng, Yan, Xie, Kun, Yin, Yanxin, Li, Bingyu, Pi, Chenyu, Xu, Xiaoqing, Huang, Tao, Zhang, Jingming, Wang, Bo, Gu, Hua, Fang, Jianmin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8879513/ https://www.ncbi.nlm.nih.gov/pubmed/35207448 http://dx.doi.org/10.3390/life12020157

Ejemplares similares

Novel anti-CD30/CD3 bispecific antibodies activate human T cells and mediate potent anti-tumor activity
por: Faber, Mary L., et al.
Publicado: (2023)

Site-specific PEGylation of an anti-CEA/CD3 bispecific antibody improves its antitumor efficacy
por: Pan, Haitao, et al.
Publicado: (2018)

Asymmetric anti-CLL-1×CD3 bispecific antibody, ABL602 2+1, with attenuated CD3 affinity endows potent antitumor activity but limited cytokine release
por: Lee, Eunhee, et al.
Publicado: (2023)

Suppression of c-Met-Overexpressing Tumors by a Novel c-Met/CD3 Bispecific Antibody
por: Huang, Lei, et al.
Publicado: (2020)

Targeting immunotherapy for bladder cancer using anti‐CD3× B7‐H3 bispecific antibody
por: Ma, Wanru, et al.
Publicado: (2018)

Bispecific Antibody‐directed Antitumor Activity of Human CD4(+) Helper/Killer T Cells Induced by Anti–CD3 Monoclonal Antibody plus Interleukin 2
por: Nishimura, Takashi, et al.
Publicado: (1991)

Targeting immunotherapy for bladder cancer by using anti-CD3 × CD155 bispecific antibody
por: Ma, Wanru, et al.
Publicado: (2019)

Targeting CD89 on tumor-associated macrophages overcomes resistance to immune checkpoint blockade
por: Xu, Lijun, et al.
Publicado: (2022)

A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells
por: Yu, Shengnan, et al.
Publicado: (2019)

An optimal antitumor response by a novel CEA/CD3 bispecific antibody for colorectal cancers
por: Wang, Ninghai, et al.
Publicado: (2021)

Novel potent anti-STEAP1 bispecific antibody to redirect T cells for cancer immunotherapy
por: Lin, Tsung-Yi, et al.
Publicado: (2021)

In vitro and in vivo stability and anti-tumour efficacy of an anti-EGFR/anti-CD3 F(ab')2 bispecific monoclonal antibody.
por: Negri, D. R., et al.
Publicado: (1995)

A Preclinical Population Pharmacokinetic Model for Anti‐CD20/CD3 T‐Cell‐Dependent Bispecific Antibodies
por: Ferl, Gregory Z., et al.
Publicado: (2018)

Development of a reporter gene method to measure the bioactivity of anti-CD38 × CD3 bispecific antibody
por: Xiong, Hui, et al.
Publicado: (2021)

MEK Inhibitor Augments Antitumor Activity of B7-H3-Redirected Bispecific Antibody
por: Li, Hongjian, et al.
Publicado: (2020)

Targeting Human-Cytomegalovirus-Infected Cells by Redirecting T Cells Using an Anti-CD3/Anti-Glycoprotein B Bispecific Antibody
por: Meng, Weixu, et al.
Publicado: (2017)

Human endoglin-CD3 bispecific T cell engager antibody induces anti-tumor effect in vivo
por: Zhong, Liping, et al.
Publicado: (2021)

Potent CD4(+) T cell-associated antitumor memory responses induced by trifunctional bispecific antibodies in combination with immune checkpoint inhibition
por: Deppisch, Nina, et al.
Publicado: (2016)

Anti-CD22/CD20 Bispecific Antibody with Enhanced Trogocytosis for Treatment of Lupus
por: Rossi, Edmund A., et al.
Publicado: (2014)

Lipid Nanoparticle Delivery System for mRNA Encoding B7H3‐redirected Bispecific Antibody Displays Potent Antitumor Effects on Malignant Tumors
por: Huang, Cheng, et al.
Publicado: (2022)

Development of PF-06671008, a Highly Potent Anti-P-cadherin/Anti-CD3 Bispecific DART Molecule with Extended Half-Life for the Treatment of Cancer
por: Root, Adam R., et al.
Publicado: (2016)

Antitumor activity of an anti‐CD98 antibody
por: Hayes, Gregory M., et al.
Publicado: (2015)

Initial experience with the bispecific anti-CEA anti-CD3 antibody and its expected impact on future treatment for patients with colorectal cancer
por: Argiles, Guillem
Publicado: (2018)

Redirecting T-cell Activity with Anti-BCMA/Anti-CD3 Bispecific Antibodies in Chronic Lymphocytic Leukemia and Other B-cell Lymphomas
por: Martens, Anne W.J., et al.
Publicado: (2022)

Invariant NKT cells dictate antitumor immunity elicited by a bispecific antibody cotargeting CD3 and BCMA
por: Casey, Mika, et al.
Publicado: (2022)

Preparation of a Novel One-Armed Anti-c-Met Antibody with Antitumor Activity Against Hepatocellular Carcinoma
por: Yin, Yanxin, et al.
Publicado: (2019)

A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity
por: Huang, Po-Lin, et al.
Publicado: (2023)

A Novel Anti-HER2 Bispecific Antibody With Potent Tumor Inhibitory Effects In Vitro and In Vivo
por: Mohammadi, Mehdi, et al.
Publicado: (2021)

Phase I Study of Anti-CD3 x Anti-Her2 Bispecific Antibody in Metastatic Castrate Resistant Prostate Cancer Patients
por: Vaishampayan, Ulka, et al.
Publicado: (2015)

Broad reactivity and enhanced potency of recombinant anti-EGFR × anti-CD3 bispecific antibody-armed activated T cells against solid tumours
por: Huang, Manley T. F., et al.
Publicado: (2022)

Epitope mapping of anti-drug antibodies to a clinical candidate bispecific antibody
por: Schick, Arthur J., et al.
Publicado: (2022)

Correction: A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity
por: Huang, Po-Lin, et al.
Publicado: (2023)

Strengthening of antitumor effects in breast cancer from a novel B7-H4- and CD3-targeting bispecific antibody by an oncolytic virus
por: Tang, Jing, et al.
Publicado: (2022)

Functional comparison of single-chain and two-chain anti-CD3-based bispecific antibodies in gene immunotherapy applications
por: Compte, Marta, et al.
Publicado: (2014)

Tumor-Directed Blockade of CD47 with Bispecific Antibodies Induces Adaptive Antitumor Immunity
por: Dheilly, Elie, et al.
Publicado: (2018)

Overcoming the Constraints of Anti-HIV/CD89 Bispecific Antibodies That Limit Viral Inhibition
por: Yu, Xiaocong, et al.
Publicado: (2016)

A Novel Bispecific Antibody Targeting CD3 and Lewis Y with Potent Therapeutic Efficacy against Gastric Cancer
por: Chen, Jie, et al.
Publicado: (2021)

The making of multivalent gamma delta TCR anti-CD3 bispecific T cell engagers
por: van Diest, Eline, et al.
Publicado: (2023)

Antitumor Activity of an Anti-EGFR/HER2 Bispecific Antibody in a Mouse Xenograft Model of Canine Osteosarcoma
por: Tateyama, Nami, et al.
Publicado: (2022)

Combination therapy with B7H3-redirected bispecific antibody and Sorafenib elicits enhanced synergistic antitumor efficacy
por: Huang, Cheng, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_q8n7uff1i8ipp1s7gnb12n2krj